Sandoz To Set Up China Headquarters And R&D Center In Chongqing
This article was originally published in PharmAsia News
Sandoz Pharmaceutical, a subsidiary of Novartis, will set up its China headquarters and R&D center in Chongqing. The constant improvement of the city's investment environment helped convince the firm of its decision. At the same time, Sandoz is seeking to acquire Chongqing Lummy Pharmaceutical for its R&D and innovation capability. After establishing itself, Sandoz China will grow by acquisition and expanding its production capacity in the next five years. It aims to be among the local top-three spots in the sector, with revenue hitting RMB 10 billion ($1.47 billion). (Click here for more - Chinese Language)
You may also be interested in...
A pilot that used RFID tags with 2D barcodes was touted as more effective than using 2D barcodes alone in tracking drugs through the supply chain.
The current pandemic has accelerated the US FDA’s perspective on conducting remote clinical trials. The agency has published an emergency guidance to allow sponsors to continue their work, which a former FDA official says is an indication of where the agency is headed post-COVID-19.
Facing ongoing shortages, the US FDA is allowing most surgical masks to be used as personal protective equipment under a new emergency use authorization.